IO Biotech announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio plus KEYTRUDA for the treatment of first-line advanced melanoma.
The company ended the second quarter with approximately $28.1 million in cash and cash equivalents.
Corporate presentations are planned for upcoming healthcare and investment conferences.
Clinical Milestone
Clinical improvement observed in Phase 3 trial for Cylembio in advanced melanoma.
Financial Position
Ended Q2 with $28.1 million in cash, and additional funding secured for operations into Q1 2026.
Business Highlights
Presented at global healthcare conference and outlined plans for regulatory interactions.
- IO Biotech saw clinical improvement in pivotal trial results.
- Financially stable with cash on hand and additional funding.
- Increasing visibility through participation in investor conferences.
IO Biotech's focus on innovative cancer therapies and strategic presentations position them for future growth in the biopharmaceutical industry.